DBMI's Patrick Wu, Wei-Qi Wei, Scott Nelson, Qingxia "Cindy" Chen, Dan Roden, Eric Kerchberger and colleagues present a high-throughput approach to identify and validate drug repurposing candidates, integrating gene expression, drug perturbation and clinical data.
The study was published in Nature Communications on January 10, 2022. Read the study here.